An evening with Michael Milken

Proudly supported by the Prostate Cancer Foundation (USA)

By supporting Peter Mac, you can help rapidly accelerate the pace of discovery and innovation to achieve transformational breakthroughs in cancer research, treatment, and patient care. 

Donate now

For other ways to donate, to make a pledge or request further information, please see below. 

Please type your full name.
Invalid Input
Please type your email address.
I would like to: (optional)
Would_Like_To Invalid Input
Invalid Input
Invalid Input

Please review our Privacy Policy for details about how we use and store your information. 

Ways to donate

Donate online: 
https://foundation.petermac.org/donate

Direct Deposit:  
Bank: Commonwealth Bank of Australia 
Account Name: Peter MacCallum Cancer Centre Foundation 
BSB: 063012 
Account: 1025 0293 
Reference: Your full name

Cheque:  
To “Peter MacCallum Cancer Foundation” 
Locked Bag 5, A’Beckett Street, Melbourne Vic 8006

Phone: +61 412 339 901 – Sarah Hornby, Head of Philanthropy 

Email: This email address is being protected from spambots. You need JavaScript enabled to view it. 

 *If you are a DGR 2 entity please fill in the contact form above and a team member will reach out to you

 

 

 

Our Speakers

Michael Milken Headshot

Michael Milken 
Chairman, Prostate Cancer Foundation (USA)

Mike Milken has been a driving force in medical research, education, public health, and access to capital for over five decades. Fortune dubbed him "The Man Who Changed Medicine" and Forbes recognised him among "Visionaries Reimagining Our Children’s Future."

Today, Mike is the Chairman of the Prostate Cancer Foundation, the largest private funder in its field, and serves as chairman of FasterCures, advancing progress against life-threatening diseases. He co-founded the Melanoma Research Alliance and contributed to establishing the Milken Institute School of Public Health at George Washington University, offering 30 degree options.

Phil Hoffman Headshot

Professor Michael Hofman
Director, Prostate Cancer Theranostics and Imaging Centre of Excellence (ProsTIC)

Professor Hofman is a nuclear medicine physician, physician-scientist and Director of ProsTIC at Peter Mac. He was featured as the leading nuclear medicine researcher in the The Australian’s Top 250 Researchers 2024, and ranked number 1 globally by ExpertScape.

Professor Hofman led landmark research resulting in the global adoption of PSMA PET and PSMA radioligand therapy as new standards-of-care for imaging and targeted treatment for men with prostate cancer. His research contributed to FDA approval, MBS funding in Australia and a $2.1billion investment by Novartis in commercialisation.

He maintains a broad research interest in novel radiopharmaceuticals for imaging and therapy (theranostics) in oncology. Professor Hofman has active grants totalling more than $55 million dollars and he currently leads a US$10 million collaboration focused on development of 21st Century therapies for lethal forms of prostate cancer.